The View | European Union’s Covid-19 travel pass discriminates against the developing world
- Restricting the certificate to only those inoculated with four EU-approved jabs exacerbates the vaccine inequality already perpetuated by the West
- The exclusion of India’s Covishield, manufactured using the AstraZeneca formula, is particularly mind-boggling

International travel to the EU is currently suspended, but once travel resumes, these rules would likely apply to international travellers as well. The “green pass”, as it is more popularly known, will disproportionately affect people of colour, discriminating widely against Asians, Africans and much of the developing world.
At first glance, the policy seems innocuous and well-meant. It’s a digital proof of vaccination, allowing vaccinated travellers greater freedom of movement across the European Union, without the need for tiresome quarantines in every country.
However, to have this privilege, travellers must have been vaccinated with one of four EU-approved vaccines – Pfizer/BioNtech, Moderna, Johnson & Johnson and Vaxzevria, the latter developed by AstraZeneca and Oxford University in Europe and the United Kingdom.
